1. Goal: Lower drug cost so that they are affordable to patients
a. US Rate of Inflation (2017-2019) = 2.14% to 1.8%
b. CPI = 2.0%
c. CPI (health care) = 2.8% (2019)
2. Drug Cost Transparency
a. Transparency = cost
b. CA SB17: WAC >= $40 with 16% inflation in prior year, or 32% inflation in last 2 years
3. How do they differ? Are they effective? Pros/Cons
a. White House Plan
b. Congressional Action
c. Congress – Democratic Plan
4. State Plans – What are they trying to do? Pros/Cons
a. California
b. New York
5. Discount Programs
a. GoodRx
b. TimesRx
c. Misc.
6. PhRMA unregulated for innovation
a. Largest PhRMA produce 11% of leading new Rx
b. New Rx develo9ped by universities, academic centers, NIH, hospital research groups
c. 2/3 of new Rx developed by France, Germany, Japan, Switzerland and UK
d. Raw materials from China, India, Israel, Brazil, South Africa, Australia
7. Transparency
a. Shoppable vs. urgent
b. Uwe Reinhardt – Priced Out – health care spending increases private sector > public sector
c. Gag Order Bans (half-of-states)
d. 8 States – PhRMA must provide reasons for reasoning for drug cost decisions
_____
Make sure to subscribe to get the latest episode.
Contact Us:
Pharmacy Benefit News: http://www.propharmaconsultants.com/pbn.html
Email: [email protected]
Website: http://www.propharmaconsultants.com/
Facebook: https://www.facebook.com/propharmainc
Twitter: https://twitter.com/ProPharma/
Instagram: https://www.instagram.com/propharmainc/
LinkedIn: https://www.linkedin.com/company/pro-pharma-pharmaceutical-consultants-inc/
Podcast: https://anchor.fm/pro-pharma-talks
